Oliver Schoor

4.5k total citations · 1 hit paper
33 papers, 1.9k citations indexed

About

Oliver Schoor is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Oliver Schoor has authored 33 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Immunology, 18 papers in Molecular Biology and 18 papers in Oncology. Recurrent topics in Oliver Schoor's work include Immunotherapy and Immune Responses (21 papers), vaccines and immunoinformatics approaches (11 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Oliver Schoor is often cited by papers focused on Immunotherapy and Immune Responses (21 papers), vaccines and immunoinformatics approaches (11 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Oliver Schoor collaborates with scholars based in Germany, United States and France. Oliver Schoor's co-authors include Stefan Stevanović, Hans‐Georg Rammensee, Jörn Dengjel, Toni Weinschenk, Margret Müller, Florian Altenberend, Claudia Lemmel, Katharina Kreymborg, Christoph Driessen and Marianne Kraus and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Oliver Schoor

31 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Autophagy promotes MHC class II presentation of peptides from intracellular source proteins

2005 504 citations Jörn Dengjel, Oliver Schoor et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Oliver Schoor Germany	19	1.2k	951	519	438	179	33	1.9k
Christopher E. Andoniou Australia	27	1.9k 1.7×	853 0.9×	467 0.9×	710 1.6×	128 0.7×	50	3.0k
Harpreet Singh‐Jasuja Germany	20	1.7k 1.5×	1.1k 1.2×	687 1.3×	283 0.6×	162 0.9×	30	2.4k
Chamorro Somoza United Kingdom	17	1.6k 1.4×	574 0.6×	416 0.8×	238 0.5×	59 0.3×	22	2.3k
Horacio M. Serra Argentina	19	1.2k 1.0×	612 0.6×	259 0.5×	228 0.5×	69 0.4×	72	1.9k
Annaiah Cariappa United States	24	2.4k 2.1×	958 1.0×	344 0.7×	205 0.5×	139 0.8×	34	3.3k
Judy Bastin United Kingdom	17	2.6k 2.2×	909 1.0×	463 0.9×	353 0.8×	613 3.4×	20	3.9k
Norbert Hilf Germany	16	1.3k 1.1×	1.0k 1.1×	467 0.9×	218 0.5×	166 0.9×	31	1.9k
Zacarias Garcia France	29	2.0k 1.7×	649 0.7×	835 1.6×	289 0.7×	92 0.5×	42	2.7k
Gábor Pál Hungary	25	761 0.6×	736 0.8×	193 0.4×	124 0.3×	181 1.0×	62	1.9k
Sjef Verbeek Netherlands	13	1.2k 1.0×	905 1.0×	423 0.8×	158 0.4×	59 0.3×	14	2.2k

Countries citing papers authored by Oliver Schoor

Since Specialization

Citations

This map shows the geographic impact of Oliver Schoor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Schoor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Schoor more than expected).

Fields of papers citing papers by Oliver Schoor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Schoor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Schoor. The network helps show where Oliver Schoor may publish in the future.

Co-authorship network of co-authors of Oliver Schoor

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Schoor. A scholar is included among the top collaborators of Oliver Schoor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Schoor. Oliver Schoor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fritsche, Jens, Daniel J. Kowalewski, Frederik Gwinner, et al.. (2021). Pitfalls in HLA Ligandomics—How to Catch a Li(e)gand. Molecular & Cellular Proteomics. 20. 100110–100110. 18 indexed citations

Bunk, Sebastian, Martin Hofmann, Felix Unverdorben, et al.. (2019). Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER®) Molecules. Blood. 134(Supplement_1). 3368–3368. 7 indexed citations

Tsimberidou, Apostolia M., Hongbing Ma, Charles A. Stewart, et al.. (2018). Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog® IMA101) in patients with relapsed and/or refractory solid cancers. Annals of Oncology. 29. viii411–viii411. 1 indexed citations

Rampling, R., Paul Mulholland, Allan James, et al.. (2016). A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma. Clinical Cancer Research. 22(19). 4776–4785. 122 indexed citations

Halford, Sarah, R. Rampling, Allan James, et al.. (2014). Final Results from a Cancer Research Uk First in Man Phase I Trial of Ima950 (A Novel Multi Peptide Vaccine) Plus Gm-Csf in Patients with Newly Diagnosed Glioblastoma. Annals of Oncology. 25. iv364–iv364. 7 indexed citations

Neidert, Marian C., Oliver Schoor, Claudia Trautwein, et al.. (2012). Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy. Journal of Neuro-Oncology. 111(3). 285–294. 15 indexed citations

Dutoit, Valérie, Christel Herold‐Mende, Norbert Hilf, et al.. (2012). Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain. 135(4). 1042–1054. 146 indexed citations

Weinzierl, Andreas O., Dominik Maurer, Florian Altenberend, et al.. (2008). A Cryptic Vascular Endothelial Growth Factor T-Cell Epitope: Identification and Characterization by Mass Spectrometry and T-Cell Assays. Cancer Research. 68(7). 2447–2454. 42 indexed citations

Dengjel, Jörn, Maria-Dorothea Nastke, Cécile Gouttefangeas, et al.. (2006). Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas. Clinical Cancer Research. 12(14). 4163–4170. 54 indexed citations

10.

Weinzierl, Andreas O., Claudia Lemmel, Oliver Schoor, et al.. (2006). Distorted Relation between mRNA Copy Number and Corresponding Major Histocompatibility Complex Ligand Density on the Cell Surface. Molecular & Cellular Proteomics. 6(1). 102–113. 93 indexed citations

11.

Schmid, Dorothee, Jörn Dengjel, Oliver Schoor, Stefan Stevanović, & Christian Münz. (2006). Autophagy in innate and adaptive immunity against intracellular pathogens. Journal of Molecular Medicine. 84(3). 194–202. 102 indexed citations

12.

Dengjel, Jörn, Oliver Schoor, Rainer Fischer, et al.. (2005). Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proceedings of the National Academy of Sciences. 102(22). 7922–7927. 504 indexed citations breakdown →

13.

Krämer, Björn, Oliver Schoor, Tobias Krüger, et al.. (2005). MAGED4 – expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue. Cancer Biology & Therapy. 4(9). 943–948. 27 indexed citations

14.

Carralot, Jean‐Philippe, Claudia Dumrese, Reimer Rießen, et al.. (2005). CD8+ T cells specific for a potential HLA-A*0201 epitope from Chlamydophila pneumoniae are present in the PBMCs from infected patients. International Immunology. 17(5). 591–597. 8 indexed citations

15.

Tenzer, Stefan, Björn Peters, Sascha Bulik, et al.. (2005). Modeling the MHC class I pathway by combining predictions of proteasomal cleavage,TAP transport and MHC class I binding. Cellular and Molecular Life Sciences. 62(9). 1025–1037. 267 indexed citations

16.

Carralot, Jean‐Philippe, Benjamin Weide, Oliver Schoor, et al.. (2005). Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas. PubMed. 3(1). 6–6. 28 indexed citations

17.

Krüger, Tobias, Oliver Schoor, Claudia Lemmel, et al.. (2004). Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunology Immunotherapy. 54(9). 826–836. 53 indexed citations

18.

Pascolo, Steve, Florent Ginhoux, Nihay Laham-Karam, et al.. (2004). The non-classical HLA class I molecule HFE does not influence the NK-like activity contained in fresh human PBMCs and does not interact with NK cells. International Immunology. 17(2). 117–122. 8 indexed citations

19.

Probst, Jochen, Stefan Tenzer, Toni Weinschenk, et al.. (2004). A conserved sequence in the mouse variable T cell receptor α recombination signal sequence 23‐bp spacer can affect recombination. European Journal of Immunology. 34(8). 2179–2190. 3 indexed citations

20.

Walter, Steffen, Leah Herrgen, Oliver Schoor, et al.. (2003). Cutting Edge: Predetermined Avidity of Human CD8 T Cells Expanded on Calibrated MHC/Anti-CD28-Coated Microspheres. The Journal of Immunology. 171(10). 4974–4978. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact